Ginkgo Bioworks (NYSE: DNA) completed the acquisition of cell therapy platform assets of Modulus Therapeutics.
Ginkgo Bioworks (NYSE: DNA) completed the acquisition of cell therapy platform assets of Modulus Therapeutics on April 2, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5285 USD | -5.51% | -20.06% | -68.73% |
1st Jan change | Capi. | |
---|---|---|
-68.73% | 1.17B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |